Related Experiment Video
Updated: Jan 30, 2026

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
Published on: April 9, 2019
TRAIL stabilization and cancer cell sensitization to its pro-apoptotic activity achieved through genetic fusion with
Elena Brin1, Katherine Wu1, Eleanor Dagostino1
1Polaris Pharmaceuticals, San Diego, CA, USA.
Abstract:
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) binds to death receptors and induces apoptosis in various cancer cell lines while sparing normal cells. Recombinant TRAIL has shown good safety and efficacy profiles in preclinical cancer models. However, clinical success has been limited due to poor PK and development of resistance to death receptor-induced apoptosis. We have addressed these issues by creating a fusion protein of TRAIL and arginine deiminase (ADI). The fusion protein benefits from structural and functional synergies between its two components and has an extended half-life in vivo. ADI downregulates survivin, upregulates DR5 receptor and sensitizes cancer cells to TRAIL induced apoptosis. ADI-TRAIL fusion protein was efficacious in a number of cell lines and synergized with some standard of care drugs. In an HCT116 xenograft model ADI-TRAIL localized to the tumor and induced dose-dependent tumor regression, the fusion protein was superior to rhTRAIL administered at the same molar amounts.
Insights
A novel fusion protein combining Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) with arginine deiminase (ADI) demonstrates enhanced anti-cancer efficacy. This ADI-TRAIL fusion protein overcomes limitations of TRAIL alone, showing superior tumor regression in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces cancer cell apoptosis but faces clinical limitations due to poor pharmacokinetics and resistance.
- Recombinant TRAIL shows preclinical promise, yet clinical translation is hindered by suboptimal in vivo behavior and acquired resistance mechanisms.
Purpose of the Study:
- To develop and evaluate a novel fusion protein combining TRAIL with arginine deiminase (ADI) to enhance anti-cancer efficacy and overcome TRAIL resistance.
- To investigate the synergistic effects and in vivo performance of the ADI-TRAIL fusion protein in preclinical cancer models.
Main Methods:
- Construction and characterization of an ADI-TRAIL fusion protein.
- Assessment of fusion protein efficacy in various cancer cell lines and combination studies with standard-of-care drugs.
- Evaluation of ADI-TRAIL fusion protein's pharmacokinetics, tumor localization, and anti-tumor activity in HCT116 xenograft models.
Main Results:
- The ADI-TRAIL fusion protein exhibited synergistic effects, downregulating survivin and upregulating DR5 receptor expression, thereby sensitizing cancer cells to apoptosis.
- The fusion protein demonstrated significant efficacy across multiple cell lines and synergized with certain standard chemotherapeutic agents.
- In HCT116 xenografts, ADI-TRAIL localized to tumors and induced dose-dependent regression, outperforming recombinant TRAIL at equivalent molar concentrations.
Conclusions:
- The ADI-TRAIL fusion protein represents a promising therapeutic strategy by combining the apoptotic effects of TRAIL with the sensitizing properties of ADI.
- This novel fusion protein overcomes key limitations of TRAIL, offering improved pharmacokinetics and enhanced anti-tumor activity.
- ADI-TRAIL warrants further investigation as a potential next-generation cancer therapeutic agent.
Related Concept Videos
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized...
Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
RNA Stability
Nuclear Stability
To hold positively charged protons together...
Genetics of Speciation
The Extrinsic Apoptotic Pathway

